Innovent Biologics (1801) Price & Analysis

Compare

21 Followers

1801 Stock Chart & Stats

HK$92.00

-HK$0.85(-2.50%)

At close: Jan 09 4:00 PM EST

HK$92.00

-HK$0.85(-2.50%)

Day’s Range― - ―

52-Week RangeHK$28.65 - HK$109.10

Previous CloseN/A

Volume9.75M

Average Volume (3M)16.11M

Market Cap

$148.82B

Enterprise ValueHK$126.14B

Total Cash (Recent Filing)$9.54B

Total Debt (Recent Filing)$3.38B

Price to Earnings (P/E)116.9

Beta0.90

Next Earnings

Apr 01, 2026

EPS Estimate

0.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.56

Shares Outstanding1,713,520,000

10 Day Avg. Volume15,175,046

30 Day Avg. Volume16,110,837

Financial Highlights & Ratios

PEG Ratio6.48

Price to Book (P/B)4.26

Price to Sales (P/S)5.94

P/FCF Ratio-133.71

Enterprise Value/Market Cap0.85

Enterprise Value/Revenue11.04

Enterprise Value/Gross Profit14.47

Enterprise Value/Ebitda190.86

Forecast

1Y Price Target

$115.52

Price Target Upside25.56% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering14

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial PerformanceInnovent reported significant revenue growth, achieving 51% of prior full-year forecasts and exceeding expectations.

Research And DevelopmentThe advancement of IBI363 towards global development with FDA clearance for a key trial marks a major milestone in its development.

Strategic PartnershipsInnovent has announced a global strategic partnership with Takeda on several key oncology assets, designed to expand Innovent’s global footprint.

Bears Say

Innovent Biologics News

Innovent Biologics announces initial data of IBI3003

Innovent Biologics (IVBXF) announced the initial data of the first-in-human trial of IBI3003, a novel trispecific antibody targeting...

10h ago

Innovent Biologics enters HSI, two other major indices

Innovent Biologics (IVBXF) announced that it has been successfully added as a constituent stock of the Hang Seng...

8d ago

Innovent Biologics, Sanegene Bio announces results on IBI3016

Innovent Biologics (IVBXF) jointly announced with Sanegene Bio USA that the preliminary results from the first-in-human, FIH, Phase...

28d ago

Innovent Biologics’ Seven Drugs Added to China’s National Reimbursement List

Innovent Biologics ( ($HK:1801) ) has shared an update. Innovent Biologics has announced the inclusion of seven innovative...

1d ago

Innovent Biologics Grants Share Options to Boost Employee Engagement

Innovent Biologics ( ($HK:1801) ) has issued an update. Innovent Biologics announced the grant of 15,000 share options...

3d ago

Innovent Biologics Closes Strategic Partnership with Takeda

Innovent Biologics ( ($HK:1801) ) has issued an announcement. Innovent Biologics, Inc. has successfully closed a global strategic...

4d ago

Innovent Biologics’ PECONDLE® Approved for Psoriasis Treatment in China

Innovent Biologics ( ($HK:1801) ) has provided an announcement. Innovent Biologics has announced that its new drug, PECONDLE®...

10d ago

Innovent’s Mazdutide 9mg Application Accepted by China’s NMPA

Innovent Biologics ( ($HK:1801) ) just unveiled an update. Innovent Biologics has announced that China’s National Medical Products...

13d ago

Innovent Biologics Achieves 40% Revenue Growth in Q3 2025

Innovent Biologics ( ($HK:1801) ) has provided an update. Innovent Biologics reported a 40% year-on-year increase in product...

1M ago

Innovent Biologics and Takeda Partnership Fuels Global Expansion and Strengthens Buy Rating

Innovent Biologics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jill Wu from...

2M ago

Innovent Biologics announces global strategic partnership with Takeda

Innovent Biologics (IVBXF) announced a strategic global collaboration with Takeda (TAK) to advance next-generation IO and ADC cancer...

2M ago

TAK

Innovent Biologics Partners with Takeda for Global Cancer Therapy Development

Innovent Biologics ( ($HK:1801) ) has provided an announcement. Innovent Biologics has entered a global strategic collaboration with...

2M ago

Innovent Biologics’ Mazdutide Approved in China for Type 2 Diabetes

Innovent Biologics ( ($HK:1801) ) has shared an announcement. Innovent Biologics has announced that its new drug, mazdutide,...

3M ago

Innovent Biologics Grants Share Options to Boost Employee and Director Engagement

Innovent Biologics ( ($HK:1801) ) has shared an update. Innovent Biologics announced the grant of 20,800 share options...

3M ago

1801 FAQ

What was Innovent Biologics’s price range in the past 12 months?

Innovent Biologics lowest stock price was HK$28.65 and its highest was HK$109.10 in the past 12 months.

What is Innovent Biologics’s market cap?

Innovent Biologics’s market cap is $148.82B.

When is Innovent Biologics’s upcoming earnings report date?

Innovent Biologics’s upcoming earnings report date is Apr 01, 2026 which is in 114 days.

How were Innovent Biologics’s earnings last quarter?

Innovent Biologics released its earnings results on Aug 27, 2025. The company reported HK$0.561 earnings per share for the quarter, beating the consensus estimate of HK$0.198 by HK$0.363.

Is Innovent Biologics overvalued?

According to Wall Street analysts Innovent Biologics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Innovent Biologics pay dividends?

Innovent Biologics does not currently pay dividends.

What is Innovent Biologics’s EPS estimate?

Innovent Biologics’s EPS estimate is 0.04.

How many shares outstanding does Innovent Biologics have?

Innovent Biologics has 1,713,520,000 shares outstanding.

What happened to Innovent Biologics’s price movement after its last earnings report?

Innovent Biologics reported an EPS of HK$0.561 in its last earnings report, beating expectations of HK$0.198. Following the earnings report the stock price went down -4.961%.

Which hedge fund is a major shareholder of Innovent Biologics?

Currently, no hedge funds are holding shares in HK:1801

Innovent Biologics Stock Smart Score

Outperform

Fundamentals

Return on Equity

8.41%

Trailing 12-Months

Asset Growth

17.88%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Innovent Biologics

Innovent Biologics (1801) is a leading biopharmaceutical company based in China, specializing in the research, development, and commercialization of innovative biologics for the treatment of cancer and autoimmune diseases. The company focuses on monoclonal antibodies, biosimilars, and other biologic therapies, aiming to address unmet medical needs with high-quality, cost-effective solutions. Innovent operates within the biopharmaceutical sector and is dedicated to advancing healthcare through innovation and collaboration.

Innovent Biologics (1801) Earnings & Revenues

Historic Earnings Reports

1801 Stock 12 Month Forecast

Average Price Target

HK$115.52

▲(25.56% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"31":"HK$31","138":"HK$138","57.75":"HK$57.8","84.5":"HK$84.5","111.25":"HK$111.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":137.38823487033184,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$137.39</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":115.5178452792,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$115.52</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":99.991437314652,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$99.99</span>\n  </div></div>","useHTML":true}}],"tickPositions":[31,57.75,84.5,111.25,138],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,87,90.8760180669486,94.7520361338972,98.62805420084581,102.50407226779441,106.38009033474302,110.25610840169162,114.13212646864022,118.00814453558883,121.88416260253743,125.76018066948603,129.63619873643464,133.51221680338324,{"y":137.38823487033184,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,87,89.19368040609231,91.38736081218461,93.58104121827692,95.77472162436923,97.96840203046153,100.16208243655385,102.35576284264616,104.54944324873847,106.74312365483077,108.93680406092308,111.13048446701538,113.32416487310769,{"y":115.5178452792,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,87,87.9993413318963,88.99868266379262,89.99802399568892,90.99736532758523,91.99670665948153,92.99604799137785,93.99538932327415,94.99473065517046,95.99407198706677,96.99341331896308,97.99275465085938,98.9920959827557,{"y":99.991437314652,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":35.05,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.65,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.6,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.75,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.85,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.75,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.4,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >